Hims & Hers CFO Oluyemi Okupe sells $354,860 in stock

Hims & Hers Health CFO Oluyemi Okupe divested 12,313 shares of the company’s Class A Common Stock on September 17, 2026, selling them at $28.82 per share, generating a total of $354,860. This action occurred under a pre-existing Rule 10b5-1 trading plan initiated on May 20, 2026.

Post-sale, Okupe now owns 251,804 shares directly, with an additional 7,853 shares indirectly held by the Oluyemi Okupe Separate Property Trust. Analysts suggest Hims & Hers Health is currently overvalued, with InvestingPro indicating this view. Investors can gain further insights through a Pro Research Report on Hims & Hers, available among 1,400+ US equities on the platform.

Hims & Hers Health reported its second-quarter 2026 earnings, leading Truist Securities to raise its stock price target to $32, maintaining a Hold rating. This upgrade was based on a review of proprietary card data and earnings disclosures. Conversely, Barclays adjusted its price target downward to $35, citing margin concerns despite anticipating faster revenue growth. Barclays now estimates Hims & Hers' fiscal 2026-2028 revenues to surpass earlier projections.

Moreover, Hims & Hers expanded its offerings by launching branded GLP-1 weight-loss medications in Australia through its Pilot platform, following the acquisition of digital health platform Eucalyptus. However, the company faces challenges, including enrollment in Visa’s Acquirer Monitoring Program due to a rise in customer credit card disputes within its weight-loss subscription business. This has led to an $8 surcharge per dispute, totaling nearly $75,000.

KeyBanc continues to maintain a Sector Weight rating on Hims & Hers, recognizing the company’s effective application of artificial intelligence with payback periods within 12 months.